Top Page
Global Bio-chem Technology Group Co. Ltd.
(0809)
Global Bio-chem Technology Group Co. Ltd. (0809) vs. iShares MSCI Hong Kong ETF (EWH)
Global Bio-chem Technology Group Co. Ltd. Business Overview & Revenue Model
Global Bio-chem Technology Group Co. Ltd. Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.00B | 1.37B | 372.28M | 746.55M | 848.87M | Gross Profit |
| 218.68M | 43.64M | 34.60M | 48.35M | 74.10M | EBIT |
| -139.74M | -318.17M | -849.40M | -973.85M | -964.93M | EBITDA |
| 16.85M | 4.69B | -469.06M | 785.63M | -1.39B | Net Income Common Stockholders |
| 769.60M | 4.22B | -1.52B | -435.39M | -2.43B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 149.43M | 315.41M | 41.77M | 21.81M | 153.32M | Total Assets |
| 4.54B | 5.21B | 5.85B | 6.48B | 7.60B | Total Debt |
| 3.69B | 5.45B | 8.15B | 8.44B | 8.96B | Net Debt |
| 3.61B | 5.36B | 8.11B | 8.42B | 8.81B | Total Liabilities |
| 6.50B | 9.25B | 13.64B | 13.18B | 13.62B | Stockholders Equity |
| -1.95B | -4.04B | -7.54B | -6.52B | -5.86B |
| Cash Flow | Free Cash Flow | |||
| 76.04M | -94.24M | -94.19M | -501.02M | -43.02M | Operating Cash Flow |
| 76.04M | -50.46M | -88.01M | -475.21M | -26.19M | Investing Cash Flow |
| -535.00K | -14.37M | -413.00K | 392.59M | 120.09M | Financing Cash Flow |
| -76.06M | 165.81M | 109.75M | -48.66M | -25.87M |
Global Bio-chem Technology Group Co. Ltd. Technical Analysis
Global Bio-chem Technology Group Co. Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | HK$659.15M | 0.89 | ― | 45.65% | -81.70% | ||
51 Neutral | $2.04B | -1.23 | -21.09% | 3.96% | 2.90% | -30.45% | |
| $1.03B | 20.91 | -0.91% | 1.10% | ― | ― | ||
| $3.55B | 12.17 | 8.95% | 4.36% | ― | ― | ||
| $5.25B | 12.41 | 5.64% | 1.68% | ― | ― | ||
73 Outperform | HK$1.88B | 3.07 | 18.33% | 4.80% | -9.95% | 67.56% | |
41 Neutral | HK$47.98M | ― | -14.71% | ― | 23.76% | 5.26% |
Global Bio-chem Technology Group Co. Ltd. Corporate Events
Global Bio-chem Technology Group Co. Ltd. has announced a Suppliers Debt Restructuring Arrangement to address overdue payables amounting to RMB461.1 million, involving over 130 independent suppliers. This arrangement includes a debt-to-equity conversion and an equity swap, ultimately allowing suppliers to convert their debt into equity in a subsidiary, Century Dacheng, and then into shares of the company. This strategic move is expected to result in a net gain of no less than HK$190.0 million for the company, improving its financial standing and potentially enhancing shareholder value.
Global Bio-chem Technology Group Co. Ltd. has announced the relaunch of the Boiler Refurbishment Project at Changchun Dahe, which involves entering into an EPC Contract through a public tender process. The tender, which commenced on May 26, 2025, will determine the contractor responsible for engineering design, procurement, and construction works. The project is significant as it may constitute a discloseable transaction under the Listing Rules, potentially impacting the company’s operations and market positioning.
Global Bio-chem Technology Group Co. Ltd. has entered into a strategic cooperation framework agreement with Hefei Hechen Bio-tech Company Limited to establish a synthetic biology pilot testing platform at its Xinglongshan production site. This collaboration aims to leverage both companies’ strengths in synthetic biology to support the development of bio-manufacturing industries in Jilin Province. The initiative marks a significant step towards resuming operations at the Xinglongshan site, which is expected to improve operational efficiency and strengthen the company’s working capital.
Global Bio-chem Technology Group Co. Ltd. announced that all resolutions proposed at its Annual General Meeting were approved by shareholders. The resolutions included the re-election of directors, approval of financial statements, and granting of mandates for share dealings, indicating strong shareholder support and potentially enhancing the company’s governance and operational flexibility.
Global Bio-chem Technology Group Co. Ltd. has announced its upcoming annual general meeting scheduled for May 9, 2025, in Hong Kong. Key agenda items include the approval of the 2024 financial statements, re-election of directors, and authorization for the board to manage director and auditor remunerations. Additionally, the company seeks approval to allot and issue new shares, which could impact its capital structure and shareholder value.
Global Bio-chem Technology Group Co. Ltd. announced its financial results for the year ending December 31, 2024, reporting a significant increase in revenue from HK$1,373,938,000 in 2023 to HK$2,001,095,000 in 2024. Despite a rise in gross profit and other income, the company experienced a decrease in total comprehensive income due to substantial other expenses and finance costs, resulting in a total comprehensive income of HK$358,324,000, down from HK$3,508,029,000 the previous year.
Global Bio-chem Technology Group Co. Ltd. has announced a board meeting scheduled for March 28, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the payment of a final dividend, which could impact stakeholders and the company’s financial outlook.
Global Bio-chem Technology Group Co. Ltd. has issued a profit warning, indicating a significant decrease in net gain for the year ending December 31, 2024, compared to the previous year. Despite an increase in revenue and gross profit, the expected net gain is lower due to the absence of a substantial one-off gain from a debt restructuring agreement in the prior year. The company has completed the disposal of eight subsidiaries, resulting in a one-off gain, but this was not enough to match the previous year’s financial performance.